The publication of this infographic was funded by AstraZeneca, and is intended for US Healthcare Professionals. Expert opinions are shared in this program and may differ from the approved capivasertib (TRUQAP®) labeling. Please see full Prescribing Information, including Patient Information when making treatment decisions.
This infographic outlines key steps for the prevention, monitoring, and treatment of hyperglycemia in patients with breast cancer receiving capivasertib. It includes an illustrative example of how to manage a patient who develops hyperglycemia, based on prescribing information and expert panel consensus.
Explore how to prepare proactively before Day 1 of capivasertib therapy, when and how to monitor fasting glucose, and what to tell patients. The infographic also covers how to approach first-line and second-line antihyperglycemic treatment, and when to withhold, resume, or permanently discontinue capivasertib.
